21 Proteomics, Genomics & Microarrays


complex, offers enhanced capabilities and is better suited for use by trained personnel in clinical or decentralised settings.


Both platforms operate on the principle of capacitive coupling between a functionalised gate and a polarising conducting system. This interaction induces a shift in threshold voltage (VT) and transistor current (ID) upon binding of markers to the biofunctionalized gate. The disposable accessory cartridges, integral to both platforms, incorporate biofunctionalized gates specifi c to the marker being detected, as well as non- biofunctionalized reference gates to ensure stability during the assay. These cartridges are customised for different applications, ranging from detecting pathogens like the SARS-Cov2 virus in self-sampled saliva to diagnosing pancreatic cancer precursors in blood plasma.


Connectivity is a key feature of SiMoT technology. Electronic readers are seamlessly integrated with smart devices via Bluetooth or USB, enabling direct data transfer and facilitating real-time analysis. This connectivity streamlines data management, analysis, and reporting, enhancing the overall effi ciency of the testing process. Moreover, SiMoT is designed to be ultra-portable and handheld, operating in fully equipment-free environments with minimal infrastructure requirements.


Sustainability is a core consideration in the development of SiMoT technology. Efforts are underway to explore the use of biodegradable materials derived from biomass and food waste, along with additive printing techniques, to minimise environmental impact. This sustainable approach extends to the design of fully recyclable, battery-less Si- integrated circuit readers, further reducing the ecological footprint of the technology.


Scalability is another crucial aspect of SiMoT technology. The platforms have demonstrated exceptional performance, achieving single-molecule detection limits


with diagnostic sensitivity and selectivity exceeding 95%. This level of performance has signifi cant implications for disease diagnosis, particularly in less developed countries where access to healthcare resources is limited. SiMoT’s rapid assay capabilities, delivering results in approximately 20 minutes for single markers and an hour for the array, further enhance its utility in clinical settings.


SiMoT’s versatility extends to its ability to assay both proteins/antigens and nucleic acid strand markers simultaneously, offering a comprehensive approach to disease diagnosis. The technology’s unique combination of features, including the amplifi cation effect, Boolean assay operation, and utilisation of Artifi cial Intelligence algorithms, sets it apart as a superior POCT technology, surpassing existing technologies like CRISPR- based assays.


In terms of cost-effectiveness, SiMoT offers competitive pricing, with cost estimates indicating affordability for both readers and cartridges. Even in low-resource settings, where the cost of the reader can be shared among multiple patients, SiMoT remains an accessible option for healthcare providers. Moreover, as production scales up, costs are expected to decrease further, making SiMoT even more accessible to a wider population.


Overall, SiMoT technology represents a paradigm shift in POCT, offering unmatched performance, versatility, and sustainability. Its potential to revolutionise disease diagnosis and management, particularly in resource-limited settings, underscores its importance in advancing global healthcare initiatives. With ongoing research and development efforts focused on refining and expanding its capabilities, SiMoT is poised to make a lasting impact on healthcare delivery worldwide.


Read, Share and Comment on this Article, visit: www.labmate-online.com/article


New dyes and antibody markers for enhanced immunology research Bio-Rad Laboratories, Inc has announced the release of three new StarBright™ Red Dyes - StarBright Red 715, 775, and 815 - and the expansion of its StarBright Violet Dye series with 29 additional highly validated antibodies. With a total of 32 dyes now available, Bio- Rad’s StarBright Dyes offer enhanced options for conventional and full-spectrum flow cytometry in immunology research.


The StarBright Dyes, proprietary fluorescent nanoparticles conjugated to flow-validated antibodies, provide exceptional brightness with narrow excitation and emission profiles. The new StarBright Red Dyes are excitable by the 640 nm laser, offering brightness comparable to existing dyes while exhibiting minimal background and stability in fixatives.


Compatible with most experimental protocols and flow cytometers, including the Bio-Rad ZE5 Cell Analyser, StarBright Dyes ensure reproducible and consistent staining with minimal lot-to-lot variation. Additionally, these dyes resist photobleaching, maintaining signal integrity even after fixation.


The expanded range of antibody markers includes targets for human, mouse, dog, cow, and pig species, enhancing the versatility of StarBright Violet Dyes for a variety of research applications.


Hilary Mavor, Marketing Director, Life Science Group, Bio-Rad, stated: “The Bio-Rad StarBright Dye portfolio offers superior alternatives to


existing dyes, providing researchers with greater choice and flexibility when building multicolour panels in conventional and full-spectrum flow cytometry.” More information online: ilmt.co/PL/7nE0


62589pr@reply-direct.com


Cutting-edge genomic array advances global pharmacogenomic research


Thermo Fisher Scientific responds to the demand for a more inclusive representation of the human genome with the introduction of its latest and most diverse genomic array, the AxiomTM PangenomiX Array*. Built upon the first draft of the pangenome, which incorporated full genetic blueprints from 47 individuals worldwide, this high-throughput microarray offers unparalleled coverage for population-scale disease investigations and pharmacogenomic research.


The prevailing large-scale genomic datasets primarily rely on European and Caucasian cohorts, limiting the understanding of genetic variations in other populations, including African, Asian, and mixed populations. The PangenomiX Array aims to address this gap by providing comprehensive genomic insights across diverse ethnicities, supporting proactive healthcare models emphasising the role of genetics in disease risk and drug response.


Distinguishing itself as the only research solution combining four assays in a single test - SNP genotyping, whole genome copy number variant detection, fixed copy number discovery, blood, and HLA typing - the PangenomiX Array facilitates advancements in disease risk and detection, population-scale research programs, ancestry testing, wellness assessments, drug efficacy trials, and drug development endeavours.


The array incorporates clinically relevant pharmacogenomic markers and pathogenic variants, offering researchers improved whole-genome imputation and a high degree of diversity for testing across various ethnic backgrounds. Already utilised in the analysis of nearly half a million ethnically diverse samples at a prominent US biobank, the PangenomiX Array contributes to inclusive research studies focused on preventing, diagnosing, and treating diseases.


Kim Caple, President of Genetic Sciences at Thermo Fisher Scientific, commented: “The PangenomiX Array marks a significant stride in diversifying genomic datasets, propelling population-scale disease testing to unprecedented levels. This development holds long-term implications for our understanding of human disease, drug development, pharmacogenomics, and ancestry. With its extensive coverage, cost-effectiveness, accuracy, and reproducibility, the array builds on our three decades of dedicated microarray research, aiming to empower research that enhances people’s longevity and well-being.”


More information online: ilmt.co/PL/A6k1 61777pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48